Comparison
Davunetide vs Semax
Microtubule stability and tau reduction vs rapid BDNF/NGF upregulation for cognitive lift.
This page contains affiliate links to compounds sold strictly for laboratory research use only. We may earn a commission on qualifying purchases at no additional cost to you. See our affiliate policy.
Davunetide
Microtubule-Stabilizing Neuroprotective Peptide
Nootropict½ Minutes (plasma); CNS effects persist longer
Semax
Melanocortin Neuropeptide
Nootropict½ Plasma ~5 min; CNS effect 20–24 hours
Effectiveness Profile
Davunetide
Semax
At a Glance
| Davunetide | Semax | |
|---|---|---|
| Type | Nootropic | Nootropic |
| Legal status | Research | Research |
| Half-life | Minutes (plasma); CNS effects persist longer | Plasma ~5 min; CNS effect 20–24 hours |
| Preferred route | Intranasal | Intranasal |
| Dose frequency | twice-daily | twice-daily |
| Beginner dose | 5–5 mg | 300–600 mcg |
| Intermediate dose | 15–30 mg | 600–1200 mcg |
| Advanced dose | 30–60 mg | 1200–2000 mcg |
| Cycle length | 8–52 wks | 2–4 wks |
| Bioavailability | — | 70% |
| Time to peak | 0.5h | 0.5h |
| Active duration | 12h | 22h |
| Storage | Lyophilized: -20°C long-term, 2–8°C short-term. Reconstituted nasal spray: 2–8°C refrigerated, use within 28 days. | 2–8°C refrigerated; discard reconstituted solution after ~30 days |
| PCT required | No | No |
| Ancillaries required | No | No |
| Safe for women | Yes | Yes |
Verdict
Davunetide wins for long-term neuroprotection through microtubule stabilization, tauopathy risk mitigation, and safety in year-long protocols. Its side effect profile is on par with placebo even at maximal dosing, and it carries minimal hormonal or mood disruption.
Semax wins for rapid cognitive enhancement, immediate focus/mood effects, robust BDNF/NGF upregulation, and broad nootropic versatility. It is also far more accessible, faster-acting, and ideal for acute or stackable cognitive protocols.
Pick A or B?
Pick Davunetide if:
- The research goal is long-term neuronal resilience, dendritic stability, or tauopathy risk reduction (e.g., AAS or stimulant-heavy models).
- A clean, non-stimulant peptide with a year-long proven safety record is required.
- Stacking with BDNF / NGF modulators for comprehensive neuroprotection is the priority.
- Interest centers on axonal transport, microtubule repair, or preclinical neurodegeneration mechanisms.
- Minimal subjective or acute effect is acceptable in exchange for stronger cellular insurance.
Pick Semax if:
- Research endpoints require rapid, pronounced increases in BDNF/NGF or cognitive performance.
- The protocol calls for a clean mood-lift or focus agent without stimulant side effects.
- Acute neuroprotection (TBI, stroke models) or cognitive enhancement is the primary target.
- Stack synergy with looksmaxxing, nootropic, or AAS regimens is needed for mood support.
- A compound with immediate, titratable cognitive or emotional effects is prioritized over structural neuroprotection.
Where to Buy
This comparison is presented for informational and educational purposes only. The compounds described may be research chemicals, prescription-only, or regulated substances in your jurisdiction. Consult a qualified medical professional before using any compound. This is not medical advice.